Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
2001 1
2003 1
2004 1
2005 2
2007 1
2008 2
2010 9
2011 9
2012 15
2013 19
2014 19
2015 6
2016 11
2017 6
2018 8
2019 8
2020 11
2021 12
2022 4
2023 14
2024 13
2025 17

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

163 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial.
Kurtz JE, Pujade-Lauraine E, Oaknin A, Belin L, Leitner K, Cibula D, Denys H, Rosengarten O, Rodrigues M, de Gregorio N, Martinez García J, Petru E, Kocián R, Vergote I, Pautier P, Schmalfeldt B, Gaba L, Polterauer S, Mouret Reynier MA, Sehouli J, Churruca C, Selle F, Joly F, D'Hondt V, Bultot-Boissier É, Lebreton C, Lotz JP, Largillier R, Heudel PE, Heitz F; ATALANTE/ENGOT-ov29 Investigators. Kurtz JE, et al. J Clin Oncol. 2023 Oct 20;41(30):4768-4778. doi: 10.1200/JCO.23.00529. Epub 2023 Aug 29. J Clin Oncol. 2023. PMID: 37643382 Free PMC article. Clinical Trial.
Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.
Blay JY, Chevret S, Le Cesne A, Brahmi M, Penel N, Cousin S, Bertucci F, Bompas E, Ryckewaert T, Soibinet P, Boudou-Rouquette P, Saada Bouzid E, Soulie P, Valentin T, Lotz JP, Tosi D, Neviere Z, Cancel M, Ray-Coquard I, Gambotti L, Legrand F, Lamrani-Ghaouti A, Simon C, Even C, Massard C. Blay JY, et al. Among authors: valentin t. Lancet Oncol. 2023 Aug;24(8):892-902. doi: 10.1016/S1470-2045(23)00282-6. Epub 2023 Jul 7. Lancet Oncol. 2023. PMID: 37429302 Clinical Trial.
Primary cutaneous/subcutaneous Ewings sarcoma.
Valentin T, Winter S, Martin V, Csanyi M, Marec Berard P, Laurence V, Gaspar N. Valentin T, et al. Bull Cancer. 2025 Jun;112(6):611-618. doi: 10.1016/j.bulcan.2023.10.011. Epub 2025 Mar 11. Bull Cancer. 2025. PMID: 40074591 Review.
Role of 18F-FDG-PET/CT in the initial staging of very high-risk Ewing Sarcoma in a prospective multicentric Phase II Study: Is there still a place for bone marrow sampling?
Jehanno N, Corradini N, Gaspar N, Brahmi M, Valentin T, Revon Rivière G, Lervat C, Probert J, Entz-Werle N, Mansuy L, Plantaz D, Rios M, Saumet L, Verité C, Castex MP, Thebaud E, Cassou-Mounat T, Plissonnier AS, Mosseri V, Cordero C, Laurence V. Jehanno N, et al. Among authors: valentin t. Br J Cancer. 2024 Nov;131(10):1605-1612. doi: 10.1038/s41416-024-02864-8. Epub 2024 Oct 8. Br J Cancer. 2024. PMID: 39379569 Clinical Trial.
Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab.
Toulmonde M, Guégan JP, Spalato-Ceruso M, Valentin T, Bahleda R, Peyraud F, Rey C, Kind M, Cantarel C, Bellera C, Vanhersecke L, Bessede A, Italiano A. Toulmonde M, et al. Among authors: valentin t. Signal Transduct Target Ther. 2025 Jun 27;10(1):202. doi: 10.1038/s41392-025-02278-9. Signal Transduct Target Ther. 2025. PMID: 40579407 Free PMC article. Clinical Trial.
Investigating the prognostic impact of NY-ESO-1 expression and HLA subtypes in metastatic synovial sarcoma.
Dufresne A, Pokras S, Meurgey A, Chabaud S, Toulmonde M, Bompas E, Le Cesne A, Robin YM, Duffaud F, Valentin T, El Zein S, Leroux A, Dubray-Longeras P, Firmin N, de Pinieux G, Noal S, Delfour C, Bollard J, Tonon L, Biette A, Gadot N, Attignon V, Jean-Denis M, Woessner M, Klohe E, Thayaparan T, Eleftheriadou I, Blouch K, Nathenson MJ, Blay JY. Dufresne A, et al. Among authors: valentin t. ESMO Open. 2024 Aug;9(8):103645. doi: 10.1016/j.esmoop.2024.103645. Epub 2024 Aug 16. ESMO Open. 2024. PMID: 39153316 Free PMC article.
[Recurrent or refractory Osteosarcoma and Ewing sarcoma-French guidelines from the FSG/NETSARC and GroupOs groups].
Brahmi M, Toulmonde M, Winter S, De Percin S, Valentin T, Corradini N, Gantzer J, Marec-Berard P, Gouin F, Claude L, Ducassou A, Gaspar N, Tlemsani C, Berlanga P; GroupOs (Groupe de travail multidisciplinaire des tumeurs osseuses français). Brahmi M, et al. Among authors: valentin t. Bull Cancer. 2025 Jun;112(6):601-610. doi: 10.1016/j.bulcan.2024.03.010. Epub 2025 Apr 10. Bull Cancer. 2025. PMID: 40216575 French.
Improved nationwide survival of sarcoma patients with a network of reference centers.
Blay JY, Penel N, Valentin T, Anract P, Duffaud F, Dufresne A, Verret B, Cordoba A, Italiano A, Brahmi M, Henon C, Amouyel T, Ray-Coquard I, Ferron G, Boudou-Rouquette P, Tlemsani C, Salas S, Rochwerger R, Faron M, Bompas E, Ducassou A, Gangloff D, Gouin F, Firmin N, Piperno-Neumann S, Rios M, Ropars M, Kurtz JE, Le Nail LR, Bertucci F, Carrere S, Llacer C, Watson S, Bonvalot S, Leroux A, Perrin C, Gantzer J, Pracht M, Narciso B, Monneur A, Lebbe C, Hervieu A, Saada-Bouzid E, Dubray-Longeras P, Fiorenza F, Chaigneau L, Nevieres ZM, Soibinet P, Bouché O, Guillemet C, Spano JP, Ruzic JC, Isambert N, Vaz G, Meeus P, Karanian M, Ngo C, Coindre JM, De Pinieux G, Le Loarer F, Ducimetiere F, Chemin C, Morelle M, Toulmonde M, Le Cesne A. Blay JY, et al. Among authors: valentin t. Ann Oncol. 2024 Apr;35(4):351-363. doi: 10.1016/j.annonc.2024.01.001. Epub 2024 Jan 20. Ann Oncol. 2024. PMID: 38246351 Free article.
Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial.
Penel N, Italiano A, Wallet J, Chaigneau L, Verret B, Firmin N, Watson S, Valentin T, Bompas E, Bertucci F, Brahmi M, Henon C, Brunot A, Spalato-Ceruso M, Vanseymortier M, Heyman-Decoupigny E, Ryckewaert T, Le Deley MC, Perrin C, Blay JY. Penel N, et al. Among authors: valentin t. Ann Oncol. 2025 Aug;36(8):944-953. doi: 10.1016/j.annonc.2025.03.024. Epub 2025 Apr 8. Ann Oncol. 2025. PMID: 40210087 Clinical Trial.
163 results